<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819558</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-WT1/IPC 2011-006</org_study_id>
    <nct_id>NCT01819558</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy</brief_title>
  <acronym>ALLO-WT1</acronym>
  <official_title>Etude Phase I/II d'immunothérapie Par protéine recWT1-A10+AS01B après Greffe allogénique de Cellules Souches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, underwent
      allogeneic stem cell transplantation from HLA-identical donor (related or unrelated) after
      reduced-intensity conditioning regimen.

      If WT1 expression is detectable on tumor cells, they will receive an immune therapy 60 days
      after allograft.

      6 administrations every 2 weeks of the protein recwt1-A10+AS01B will be administrated.

      The safety and immunological efficacy of this immune therapy after hematopoietic stem cells
      transplantation with reduced intensity conditioning will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>30 days</time_frame>
    <description>Dose limit toxicity (adverse event according to CTCAE V4.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>immune response</measure>
    <time_frame>up to 60 weeks after treatment</time_frame>
    <description>The specific WT1 antibody induced by the vaccination will be evaluated by the technic ELISA in UE/ml.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>immune therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 administration every 2 weeks of intra-muscular 200 micrograms of protein recwt1-A10+AS01B at week 1, 3, 5, 7, 9 and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recwt1-A10+AS01B</intervention_name>
    <arm_group_label>immune therapy</arm_group_label>
    <other_name>immune therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients older than 18 and younger than 65 years.

          2. Karnofsky ≥ 70 %.

          3. Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, who
             underwent allogeneic stem cell transplantation from HLA-identical donor (related or
             unrelated) after reduced-intensity conditioning regimen.

          4. Patients in morphologic complete remission at the time of transplantation.

          5. WT1 expression detectable on tumor cells.

          6. Expected life duration more than 6 months.

          7. Creatinine clearance ≥ 50 ml/min

          8. Bilirubinemia &lt; 1.5N and ASAT &lt; 2.5N.

          9. Women of childbearing age: negative pregnancy test and effective contraception for at
             least 30 days before vaccinal immunotherapy (the same contraceptive method must be
             continued at least 2 months after the last vaccine infusion).

         10. Membership of a social security scheme or beneficiary of such a regime.

         11. Signed inform consent.

        Exclusion Criteria:

          1. Patients with severe and uncontrolled affections, especially active graft-versus-host
             disease requiring steroid treatment (&gt;0.3 mg/kg/j) and/or Mycophenolate mofetil.

          2. Pregnant or lactating women.

          3. HIV seropositive patients.

          4. Autoimmune disease (Lupus, multiple sclerosis, Chron disease…)

          5. Previous history of allergic state which could be potentially compound by a component
             of the vaccinal immunotherapy.

          6. Patients who received (or are planned to receive) another experimental treatment
             within 30 days following the first infusion of the experimental drug of this protocol.

          7. Previous history of another cancer, except if considered as probably cured by the
             investigator.

          8. Patients deprived of liberty, or under guardianship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier BLAISE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutpaolicalmettes.fr/</url>
    <description>official web site of the sponsor</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>allograft</keyword>
  <keyword>WT1 expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

